What is Amylin (Islet Amyloid Polypeptide)?

A 37-amino-acid hormone released with insulin that slows stomach emptying and signals fullness; pramlintide (Symlin) is a synthetic version.

Amylin (Islet Amyloid Polypeptide) in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?

61 registered trials · 138 indexed papers · 188 human / 43 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A 37-amino-acid hormone released with insulin that slows stomach emptying and signals fullness; pramlintide (Symlin) is a synthetic version.

Type: Peptide hormone.

Definition (National Library of Medicine)

“A pancreatic beta-cell hormone that is co-secreted with insulin. It displays an anorectic effect on nutrient metabolism by inhibiting gastric acid secretion, gastric emptying and postprandial glucagon secretion. Islet amyloid polypeptide can fold into amyloid fibrils that have been found as a major constituent of pancreatic amyloid deposits.”

  • MeSH: Islet Amyloid Polypeptide

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Amylin (Islet Amyloid Polypeptide) is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (61)

TrialPhaseStatusYearEnrolled
Postprandial Regulation of Bone Perfusion in Healthy Individualsnot yet recruiting202615
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humansrecruiting202618
Hypersensitivity to Amylin in Post-Traumatic Headachenot yet recruiting202621
Amylin-Induced Migraine Attacks Without Auranot yet recruiting202621
Tailoring Obesity Treatment TrialPhase 2/Phase 3withdrawn2025
Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintidecompleted202433
The Role of Amylin in Bone Metabolismunknown202420
A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 DiabetesPhase 2/Phase 3unknown202330
A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetescompleted202212
Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetesunknown202126
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's DiseaseEARLY_Phase 1active not recruiting202057
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot StudyEARLY_Phase 1withdrawn2020
Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreascompleted202036
Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1DPhase 2completed201918
Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcementcompleted20198
A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes MellitusPhase 1completed201924
Glucagon Counterregulation in Type 1 Diabetesterminated201813
Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patientscompleted201836
A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes MellitusPhase 1completed201824
Serum Preptin and Amylin Levels in Polycystic Ovary Syndrome Patientscompleted201780
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes MellitusPhase 1completed201534
Glycemia in Diabetic Elders TrialPhase 4terminated20132
Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellituscompleted20139
Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DMPhase 1completed201232
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese SubjectsPhase 2terminated2011213
Pramlintide Combined With Model Predictive Control Algorithmterminated20112
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass SurgeryPhase 4completed201022
Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes MellitusPhase 3unknown201040
Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DMwithdrawn2009
Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes MellitusPhase 1/Phase 2withdrawn2009
Use of Exenatide and Pramlintide to Decrease Post-prandial HyperglycemiaPhase 4completed200937
The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 DiabetesPhase 4completed200916
Myocardial Protection of Exenatide in AMIPhase 4completed2009127
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight SubjectsPhase 2completed2008636
Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With MetreleptinPhase 2completed2008274
Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 DiabetesPhase 4withdrawn2007
Demonstrate the Effects of Pramlintide on Weight Reduction in SchizophreniaPhase 4completed200733
Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes MellitusPhase 4completed20078
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 DiabetesPhase 4completed2007112
A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 DiabetesPhase 4completed200712

Peer-reviewed studies (138)

PaperAuthorsJournalYearType
Understanding the Metabolic and Endocrine Effects of Macronutrient Boluses in the Context of a Low-Carbohydrate Diet: A Randomized Crossover StudyDeru LS et al.Nutrients2026Randomized Controlled Trial
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a studyAroda VR et al.The lancet. Diabetes & endocrinology2026Randomized Controlled Trial
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 studyBuse JB et al.The lancet. Diabetes & endocrinology2026Randomized Controlled Trial
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 studyRosenstock J et al.Lancet (London, England)2026Randomized Controlled Trial
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 TrialsBrændholt Olsen M et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
A Pilot Outpatient Assessment of a Fully Closed-Loop Insulin and Pramlintide SystemOdabassian M et al.Journal of diabetes science and technology2025Randomized Controlled Trial
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of conceptBriere DA et al.Molecular metabolism2025Randomized Controlled Trial
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled studyDahl K et al.Lancet (London, England)2025Randomized Controlled Trial
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityGarvey WT et al.The New England journal of medicine2025Randomized Controlled Trial
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 DiabetesDavies MJ et al.The New England journal of medicine2025Randomized Controlled Trial
Combined training and hormones/enzymes with insulinotropic actions in individuals with overweight and type 2 diabetes mellitus: A randomized controlled trialBonfante ILP et al.European journal of sport science2024Randomized Controlled Trial
Enteropancreatic hormone changes in caloric-restricted diet interventions associate with post-intervention weight maintenanceLin H et al.Clinical nutrition (Edinburgh, Scotland)2024Randomized Controlled Trial
Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participantsGabe MBN et al.Diabetes, obesity & metabolism2024Randomized Controlled Trial
ADO09, a co-formulation of pramlintide and insulin A[amount hidden], lowers body weight versus insulin lispro in type 1 diabetesAndersen G et al.Diabetes, obesity & metabolism2024Randomized Controlled Trial
Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, CanadaCohen E et al.The Lancet. Digital health2024Randomized Controlled Trial
Efficacy and safety of co-administered once-weekly cagrilintide 2·[amount hidden] with once-weekly semaglutide 2·[amount hidden] in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trialFrias JP et al.Lancet (London, England)2023Randomized Controlled Trial
A co-formulation of pramlintide and insulin A[amount hidden] (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetesAndersen G et al.Diabetes, obesity & metabolism2023Randomized Controlled Trial
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trialLau DCW et al.Lancet (London, England)2021Randomized Controlled Trial
A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trialTsoukas MA et al.The Lancet. Digital health2021Randomized Controlled Trial
Change of plasma amylin after bariatric surgery challenged by oral glucose is associated with remission of type 2 diabetes mellitusWang JW et al.Journal of the Chinese Medical Association : JCMA2021Randomized Controlled Trial
Safety, tolerability and pharmacokinetic characterisation of DACRA KBP-042 in healthy male subjectsHenriksen K et al.British journal of clinical pharmacology2021Randomized Controlled Trial
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·[amount hidden] for weight management: a randomised, controlled, phase 1b trialEnebo LB et al.Lancet (London, England)2021Randomized Controlled Trial
Amylin Analog Pramlintide Induces Migraine-like Attacks in PatientsGhanizada H et al.Annals of neurology2021Randomized Controlled Trial
Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorderAngarita GA et al.Drug and alcohol dependence2021Randomized Controlled Trial
Acute Nutritional Ketosis and Its Implications for Plasma Glucose and Glucoregulatory Peptides in Adults with Prediabetes: A Crossover Placebo-Controlled Randomized TrialBharmal SH et al.The Journal of nutrition2021Randomized Controlled Trial
First-Phase Insulin and Amylin after Bariatric Surgery: A Prospective Randomized Trial on Patients with Insulin Resistance or Diabetes after Gastric Bypass or Sleeve GastrectomyNussbaumer R et al.Obesity facts2020Randomized Controlled Trial
Peripheral insulin and amylin levels in Parkinson's diseaseSánchez-Gómez A et al.Parkinsonism & related disorders2020Observational Study
Protein-conformational diseases in childhood: Naturally-occurring hIAPP amyloid-oligomers and early β-cell damage in obesity and diabetesAltamirano-Bustamante NF et al.PloS one2020Observational Study
Dietary Supplementation with Curcumin Reduce Circulating Levels of Glycogen Synthase Kinase-3β and Islet Amyloid Polypeptide in Adults with High Risk of Type 2 Diabetes and Alzheimer's DiseaseThota RN et al.Nutrients2020Randomized Controlled Trial
A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover TrialHaidar A et al.Diabetes care2020Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Amylin (Islet Amyloid Polypeptide)?

A 37-amino-acid hormone released with insulin that slows stomach emptying and signals fullness; pramlintide (Symlin) is a synthetic version.

How many registered human trials study Amylin (Islet Amyloid Polypeptide)?

The PeptideWhiz trial index lists 61 registered trials for Amylin (Islet Amyloid Polypeptide), the most recent from 2026.

How much published research exists on Amylin (Islet Amyloid Polypeptide)?

The PeptideWhiz paper index links 138 PubMed papers to Amylin (Islet Amyloid Polypeptide); by study type, 188 human and 43 animal studies.

Which conditions is Amylin (Islet Amyloid Polypeptide) researched for?

Atherosclerosis, cardiovascular disease & high blood pressure, Delayed gastric emptying on GLP-1 medicines, Dementia, Alzheimer's & cognitive decline, Fat loss, obesity & body recomposition, Heart repair: after heart attack, heart failure & enlarged heart, Insulin resistance, prediabetes & type 2 diabetes, Migraine, Parkinson's disease, PCOS, Post-surgical inflammation and surgery recovery.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).